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httpcense.Abstract Background: Data on risk factors for severe outcomes from 2009 pandemic inﬂuenza A
(H1N1) virus infection are limited outside of developed countries.
Aim of the study: To evaluate the characteristics and outcomes of patients with 2009 pandemic
inﬂuenza A (H1N1) in hospitalized patients in RCH, KSA and to identify factors associated with
severe outcome.
Patients and methods: We reviewed medical charts to collect data from patients hospitalized and
tested for the presence of 2009 pandemic (H1N1) infection based on clinical suspicion during the
period from July 2009 through December 2009, and we analyzed factors associated with severe ill-
ness (deﬁned as illness requiring intensive care unit admission or resulting in death).
Results: According to our case deﬁnition, there were 176 cases of positive pandemic inﬂuenza A
(H1N1) and 54 negative cases for pandemic inﬂuenza A (H1N1). Common presenting symptoms
were fever (95% of patients), sore throat (90%), and cough (83%). Laboratory ﬁndings included
signiﬁcant elevated levels of lactate dehydrogenase and creatine phosphokinase in pandemic inﬂu-
enza A (H1N1) positive cases in addition to leucopenia, lymphopenia, and neutropenia. Incidence
of diarrhea was (25%), and vomiting was (21.5%).The mortality rate was 1.13%. Factors contrib-
uting to severe outcome were young age, female sex, dyspnoea, leucopenia, neutropenia, lympho-
penia, high creatine phosphokinase level, and high lactate dehydrogenase level. On multivariate
analysis, creatine phosphokinase level and lactate dehydrogenase were risk factors for severe out-
come.ase; CPK, creatine phospho-
pital; RT-PCR, reverse tran-
DS, acute respiratory distress
staph aureus.
e Egyptian Society of Chest
g by Elsevier
of Chest Diseases and Tuberculosis. Production and hosting by Elsevier B.V.
://dx.doi.org/10.1016/j.ejcdt.2013.02.006
2 N.M. AbdelatyConclusions: Risk factors for severe 2009 H1N1 illness were similar to those observed in devel-
oped countries. A signiﬁcant number of relatively young and previously healthy positive patients
might develop severe disease associated with a robust inﬂammatory reaction.
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Inﬂuenza pandemics have been associated with increased mor-
bidity and mortality. Each pandemic is different and there are
always a series of unknowns when an inﬂuenza virus emerges
and becomes pandemic [1,2]. The pandemic inﬂuenza A
(H1N1) virus emerged in late March 2009 as an outbreak of
respiratory illness in Mexico, this was later identiﬁed as a novel
pandemic (H1N1) 2009 virus-related disease [3,4]. This virus
can cause injuries to the lungs, liver, and heart.
Reports about the rapid spread of the virus tomany countries
outside of Mexico brought the World Health Organization to
classify the global spread of the virus as an international concern
with a pandemic level of six [5]. The clinical spectrum of novel
(H1N1) 2009 infection is still being deﬁned, but both self-limited
illness and severe outcomes, including respiratory failure and
death, have been observed among identiﬁed patients. Many re-
ports showed awide clinical spectrum similar to that seen among
persons infected with earlier strains of swine-origin inﬂuenza
viruses and seasonal inﬂuenza viruses [6]. The severe illness
and deaths associated with seasonal inﬂuenza epidemics are in
large part the result of secondary complications, including pri-
mary viral pneumonia, secondary bacterial pneumonia (partic-
ularly with group A streptococcus, Staphylococcus aureus,
and Streptococcus pneumoniae) and exacerbations of underly-
ing chronic conditions [7,8].
The published studies indicate that there are differences be-
tween pandemic (H1N1) 2009 and seasonal inﬂuenza. Among
adult patients, pandemic (H1N1) 2009 affects mainly those un-
der the age of 60 years with chronic underlying diseases, preg-
nant women, and obese patients [9]. The overall mortality of
this infection is similar to that presented by seasonal inﬂuenza
and lower than previous pandemics [10], although mortality
varies considerably between countries [2]. There is also concern
that subsequent waves of inﬂuenza pandemic could be more
lethal than the ﬁrst [1].
Little information is currently available on factors associated
with severe disease in adults hospitalized for the pandemic inﬂu-
enza (H1N1) virus. Moreover, the lack of adequate data on the
natural history of pandemic (H1N1) 2009 virus infection led to
uncertainty in approach to this new pandemic in the medical
communities ofmany countries around the world [4]. To identify
risk factors for severe disease, and hence todetermine the optimal
case management and prevention, more clinical and treatment
data of the pandemic (H1N1) 2009 are needed. The aim of the
present study was to ascertain factors associated with severe dis-
ease among adults hospitalized for pandemic (H1N1) 2009 [2].
We report the characteristics and outcomes of all patients
admitted to Royal Commission Hospital, Jubail city, KSA with
presumed diagnosis of pandemic (H1N1) 2009 virus infection
from July toDecember 2009. Demographic, clinical and labora-
tory, along with outcome parameters, were analyzed in order to
identify possible factors that may suggest the diagnosis of pan-demic (H1N1) 2009 virus infection amongpatientswith aﬂu-like
illness, and furthermore, we evaluate risk factors of more severe
clinical course among these hospitalized patients.
Methods
Case deﬁnition
A case was deﬁned as a patient who was hospitalized for
>24 h with inﬂuenza-like symptoms and had laboratory detec-
tion by the reverse transcriptase-polymerase chain reaction test
of 2009 H1N1 inﬂuenza virus. For the purposes of this study,
patients were divided into two groups: severe disease and no
severe disease. Severe disease was deﬁned as the composite out-
come of intensive-care unit (ICU) admission or in-hospital
mortality. Informed consent was obtained from patients.
Recruitment of patients
The study population comprised all adult patients (n= 230),
who were admitted to RC Hospital during the 6 month period
of the analysis (July–December 2009) and tested for the presence
of 2009 pandemic (H1N1) infection based on clinical suspicion.
Wemanaged this cohort of patients with a standard protocol
that consisted of using structured forms for recording the history
and physical ﬁndings on admission, laboratory and radio-
graphic studies, and treatment, in addition to charting the pa-
tients’ progress, and results of serial laboratory and
radiographic studies. Patients’ hospital records were reviewed
retrospectively. The decision to hospitalize suspected patients
was based on comorbidity, symptom severity, hypoxia or radio-
graphic evidence of pneumonia, and abscence of social support.
Laboratory and radiographic studies
Routine serial hematologic, biochemical, and microbiological
tests were performed. Chest radiographs were obtained for
all patients and were monitored serially. Computed tomogra-
phy of the thorax was performed in select cases.
Pandemic (H1N1) 2009 virus test
Nasal and throat viral swabs (a total of three) were obtained
from suspected patients and were transferred refrigerated to
the reference laboratory for RT-PCR testing according to
WHO recommendations.
Treatment
Treatment with oseltamivir was initiated in virtually all hospi-
talized patients with suspected pandemic (H1N1) 2009 virus
infection, in addition to prophylactic antibiotics and vitamin-
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patient’s negativity for this infection based on RT-PCR. Cases
complicated with pneumonia and ARDS received antibiotics,
steroids, antioxidants, statin, low dose diuretics, double dose
of oseltamivir for 10 days.
Data collection and study design
Patient height, weight, demographic characteristics, clinical
presentation and course, in addition to co-morbid conditions,
and laboratory and radiographic ﬁndings that were contained
in hospital records were retrospectively reviewed, collected and
analyzed.
Statistical analysis
We compared the differences in demographic, clinical, and lab-
oratory measures, clinical course, and survival between pa-
tients who had documented infection by pandemic (H1N1)
2009 virus and those who did not, and further analyzing the
positive patients for the effect of demographic, clinical and lab-
oratory parameters on disease severity by using univariate and
multivariate analysis.
We used the Student’s t-test to compare normally distrib-
uted continuous variables, Wilcoxon rank sum test for non-
normally distributed variables. Chi-square test was used to
analyze dichotomized variables. Multivariable analysis
was performed using logistic regression. We used SPSS, Inc.,
Chicago, Illinois, for all analyses.Results
Demographic, clinical and laboratory parameters
We categorized patients into 2 groups: (1) those who ﬁt the
case deﬁnition of probable (H1N1) 2009 infection and hadTable 1 Demographic and clinical characteristics of admitted pa
infection.
Variable Inﬂuenza A (H1N1) positive (N= 176
Age (yrs, mean ± SD) 35 ± 18
Gender (male/female%) 36/64
Obesity (BMI P30) 35 (21)
Chronic diseases* 16 (9)
Diabetes 44 (25)
Pregnancy 2 (1.3)
Symptoms [No. of patients (%)]
Fever 167 (95)
Chills 96 (55)
Myalgia 90 (51)
Sore throat 158 (90)
Cough 146 (83)
Sputum 128 (73)
Rigors 50 (28)
Headache 125 (71)
Dyspnea 22 (12.5)
Diarrhea 44 (25)
Vomiting 38 (21.5)
All variables are described as [No. of patients (%)] unless otherwise indi
* Other than diabetes.conﬁrmed laboratory (H1N1) 2009 (n= 176) and (2) those
with negative results on conﬁrmatory tests (n= 54).
As shown in (Table 1), H1N1 virus-positive patients were
signiﬁcantly younger, more obese and tended to have fewer
comorbidities, as compared to H1N1 negative patients. In
addition, typical signs and symptoms of ﬂu-like illness such
as fever, sore throat, and cough were signiﬁcantly more
common among H1N1-positive patients. Also dyspnea, diar-
rhea and vomiting were signiﬁcantly more common among
H1N1-positive patients (Table 1). However, no signiﬁcant
difference in major laboratory values, except for more rise
in the level of creatine phosphokinase and Lactate dehydro-
genase and lower Leukocyte count, Neutrophil count and
Lymphocyte count among H1N1 virus-positive group
(Table 2).
The age of Inﬂuenza A (H1N1) Positive patients ranged
from (17–53) years vs (31–61) years for Inﬂuenza A (H1N1)
Negative. Additionally, Male/Female% was (36/64) in H1N1
positive vs. (56/44) in H1N1 Negative. Two patients (1.3%)
of H1N1 Positive were pregnant vs. 1 patient (1.8%) among
(H1N1) Negative group.
Among the patients with positive results for (H1N1) 2009,
the most common symptoms were fever (95%), sore throat
(90%), and cough (83%). In addition, 25% of patients had
diarrhea, and 21.5% had vomiting.
Treatment with oseltamivir was initiated in all patients, but
176 of the 230 (76.5%) were ultimately found to be positive for
pandemic (H1N1) 2009 infection and completed antiviral
treatment. Sixteen patients (9%) of (H1N1) Positive had
chronic medical conditions including hypertension, bronchial
asthma, IHD vs. 6 (11%) of (H1N1) Negative cases.
Clinical outcomes
Reports from Mexico, where the pandemic originated, suggest
that the new pandemic (H1N1) 2009 virus has the potential to
cause a severe illness with life-threatening respiratory compli-tients tested for the presence of pandemic (H1N1) 2009 virus
) Inﬂuenza A (H1N1) negative (N= 54) P value
46 ± 15 0.01
56/44 0.01
5 (9) 0.001
6 (11) 0.8
18 (33.3) 0.07
1 (1.8) 0.9
48 (88.8) 0.017
28 (50) 0.10
30 (55) 0.9
46 (85) 0.026
38 (72) 0.04
38 (70) 0.30
21 (39) 0.70
42 (78) 0.12
5 (9) 0.04
10 (18.5) 0.029
11 (20.3) 0.01
cated. Statistically signiﬁcant, P< 0.05.
Table 2 Laboratory characteristics of admitted patients tested for the presence of pandemic (H1N1) 2009 virus infection.
Variable Inﬂuenza A (H1N1) positive (N= 176) Inﬂuenza A (H1N1) negative (N= 54) P value
Hemoglobin level, g/dl 12.5 ± 4.7 11.9 ± 4.5 0.21
Leukocyte count, ·109 cells/L 5.0 ± 4.0 7.55 ± 3.3 0.00
Neutrophil count, ·109 cells/L 3.2 ± 2.1 5.7 ± 1.6 0.00
Lymphocyte count, ·109 cells/L 0.7 ± 0.5 1.6 ± 0. 8 0.00
Platelet count, ·109 cells/L 193 ± 150 250 ± 200 0.90
Sodium level, mmol/L 137 ± 12 139 ± 9 0.085
Potassium level, mmol/L 3.6 ± 1.0 3.9 ± 1.4 0.50
Urea level, mmol/L 12 ± 8 15.0 ± 5 0.13
Albumin level, g/L 37 ± 17 37 ± 12 0.74
Creatinine level, mmol/L 80 ± 50 69 ± 40 0.50
Alkaline phosphatase level, U/L 250 ± 225 200 ± 160 0.74
Alanine aminotransferase level, U/L 259 ± 234 90 ± 70 0.14
Creatine phosphokinase level, (IU/L) 420 ± 380 150 ± 120 0.001
Lactate dehydrogenase level, (IU/L) 400 ± 360 260 ± 210 0.00
C-reactive protein level, (mg/dl) 61.7 ± 56 55 ± 49 0.14
All variables are described as mean ± SD (standard deviation),
Statistically signiﬁcant, P< 0.05
Table 3 Clinical outcome parameters of admitted patients tested for the presence of pandemic (H1N1) 2009 virus infection.
Variable Inﬂuenza A (H1N1) positive (N= 176) Inﬂuenza A (H1N1) negative (N= 54) P value
Pneumonia 18 (10.2%) 5 (9.2%) 0.000
Respiratory failure 7 (3.98%) (4F, 3M) 1 (1.85%) 0.001
ARDS 6 (3.40%) 1 (1.85%) 0.001
Transfer to ICU 7 (3.98%) (4F, 3M) 1 (1.85%) 0.001
Mechanical ventilation
NIPV
4(2.27%) (3F, 1M)
1 (0.56%) (M)
0 1 (1.85%) 0.001
0.001
Death 2 (1.13%) (F) 0 0.023
Guillian Barre syndrome 1 (0.56%) (F) 0 0.5
Renal failure 1 (0.56%) (F) 0 0.71
DIC 2 (1.13%) (F) 0 0.012
Shock 2 (1.13%) (F) 0 0.014
Liver failure 1 (0.56%) (F) 0 0.90
All variables are described as [No. of patients (%)].
Statistically signiﬁcant, P< 0.05.
4 N.M. Abdelatycations, especially among young previously healthy people [4].
To determine whether this is also the case in our study popu-
lation we analyzed major clinical outcomes of patients in virus-
positive patients. Interestingly, although H1N1 virus-positive
patients tended to have fewer comorbidities and were younger
than the negative patients (Table 1), H1N1 virus-positive pa-
tients had more pneumonia, respiratory failure, and ARDS
(Table 3, Fig. 1).
Furthermore, there was higher rate of transfer to the ICU,
mechanical ventilation and death among patients with positive
H1N1 suggesting that pandemic (H1N1) 2009 infection tends
to be a relatively serious disease in a signiﬁcant proportion
of hospitalized patients (Table 3, Fig. 1).
Eighteen (10.2%) of (H1N1) Positive cases had radiologi-
cally conﬁrmed pneumonia vs 5 (9.2%) in negative cases. In
(H1N1) Positive cases, seven patients (3.97%) required admis-
sion to an intensive care unit, because of respiratory failure, 4
patients required mechanical ventilation and 1 patient required
NIPV. Five of the ICU admitted patients had recovered from
the acute illness and 2 died (Table 3, Fig. 1).A previously healthy 17-y-old female patient had necrotiz-
ing pneumonia, secondary bacterial infection proved by cul-
ture to be MRSA, she also developed pneumothorax,
respiratory failure and she had lobectomy after 6 months.
A previously healthy 52-year-old woman had pneumonia,
ARDS and MV, remained critical and complicated by Guillian
Barre syndrome, multiorgan failure, DIC, shock and died. An-
other 24 years old pregnant woman had pneumonia, ARDS,
MV. She remained ill and died.
Severe disease and non-severe disease
As expected, clinical outcomes were worse among the ICU pa-
tients and with higher rates of pulmonary complications that
necessitated mechanical ventilation. Notably, pulmonary com-
plications were the hallmark of more severe clinical course, re-
ﬂected by pulmonary inﬁltrates, ARDS and respiratory failure
that necessitated transfer to the ICU.
We evaluated the effect of demographic, clinical and labo-
ratory parameters of these patients on disease severity by using
Figure 1 Clinical outcome parameters of admitted patients
tested for the presence of pandemic (H1N1) 2009 virus infection.
Risk factors and prognostic criteria in 230 patients with inﬂuenza A (H1N1) infection 5univariate and multivariate analysis. Table 4 shows the associ-
ation between admission variables and severe outcome. Age,
female sex, pregnancy, dyspnoea, low leukocyte count, low
neutrophil count, low lymphocyte count, high creatine phos-
phokinase level, and high lactate dehydrogenase level were
each associated with a severe outcome. In a multivariable mod-
el of demography, clinical and laboratory characteristics; crea-
tine phosphokinase, and lactate dehydrogenase levels wereTable 4 Univariate analysis of comorbidity, demography, clinical ch
outcome in patients hospitalised with pandemic H1N1 infection dur
Variable Like
Age < 60 3.00
Gender (Female vs male) 2.76
Obesity (BMI P30) 1.7
Chronic diseases* 1.0
Diabetes 1.66
Pregnancy 3.41
Fever 1.01
Chills 0.8
Myalgia 2.0
Sore throat 2.55
Cough 1.9
Sputum 1.5
Rigors 1.8
Headache 1.0
Dyspnea 6.96
Diarrhea 1.8
Hemoglobin level 1.1
Leukocyte count 4.0
Neutrophil count 1.76
Lymphocyte count 2.40
Platelet count 1.1
Sodium level 2.0
Potassium level 1.0
Urea level 0.6
Albumin level, 1.2
Creatinine level 1.2
Alkaline phosphatase level 0.7
Alanine aminotransferase level 1.2
Creatine phosphokinase level 1.11
Lactate dehydrogenase level 1.32
C-reactive protein level 1.62
Statistically signiﬁcant, P< 0.05.
* other than diabetesfound to be signiﬁcantly associated with a severe outcome
(Table 5).Discussion
One of the major challenges in clinical practice of intensive
care and emergency medicine is early detection and to identify
the parameters predicting severe morbidity and mortality of se-
vere community respiratory infections. The emergent pan-
demic (H1N1) 2009 virus is challenging to the medical
community around the world because of its unusual rapidity
of spread and its tendency to complications among relatively
young and previously healthy patients, seemingly considered
a low risk group for inﬂuenza-induced complications. It is still
difﬁcult to predict the natural course of the disease and estab-
lish strict policies for health care providers [11,12].
In the current study, we sought to describe a cohort of 230
patients identiﬁed in RCH (KSA) who were hospitalized for
2009 pandemic inﬂuenza A (H1N1) virus infection between
July and December 2009 and to substantiate current knowl-
edge on the natural history of the disease and also suggests risk
factors for a more severe clinical course among infected
patients.
Several major conclusions may be drawn from the present
analysis. First, among hospitalized patients suspected of hav-aracteristics and selected investigations as risk factors for severe
ing the ﬁrst pandemic wave.
lihood ratio (95% CI) P value
(1.85–7.64) 0.001
(2.07–3.89) 0.01
(0.42–4.10) 0.08
(0.95–1.02) 0.08
(0.98–7.63) 0.20
(1.33–8.71) 0.01
(0.99–1.02) 0.08
(0.44–1.34) 0.50
(0.48–13.32) 0.12
(1.89–5.55) 0.10
(0.81–5.00) 0.12
(0.70–2.80) 0.30
(0.60–4.30) 0.76
(0.70–3.40) 0.18
(1.46–27.28) 0.008
(0.44–3.35) 0.90
(0.73–4.77) 0.19
(1.33–8.71) 0.010
(1.07–2.89) 0.01
(1.12–5.13) 0.02
(0.53–1.91) 0.92
(0.9–4.2) 0.08
(0.5–2.1) 0.90
(0.3–1.2) 0.2
(0.3–3.8) 0.8
(0.65–1.78) 0.764
(0.3–1.5) 0.4
(0.5–2.7) 0.7
(1.04–1.17) 0.001
(1.81–1.49) 0.001
(0.80–3.30) 0.180
Table 5 Independent risk factors of severity by multivariate
analysis.
Variable Likelihood ratio
(95% CI)
P value
Creatine phosphokinase level 3.00 (2.21–4.55) 0.001
Lactate dehydrogenase level 1.80 (1.21–2.11) 0.001
Statistically signiﬁcant, P< 0.05.
6 N.M. Abdelatying H1N1 infection, those found to be positive for the virus
tend to be younger as compared to those who are negative,
the range of age (17–53 years) was less than is commonly seen
with seasonal inﬂuenza.
Also, there was tendency to have fewer comorbidities
among H1N1 virus-positive than negative patients. Addition-
ally, positive patients for the virus were signiﬁcantly more ob-
ese, these data is consistent with many reports and
observational study from the United States showed a high
prevalence of obesity among patients hospitalized with 2009
H1N1 virus infection [13–16].
Second important ﬁnding in our analysis; as compared with
patients in the United States [8] and Japan [17] and those in
Mexico and other countries [18,19], we found that the typical
symptoms and signs of inﬂuenza, including fever, cough and
sore throat are more common among pandemic (H1N1)
2009 virus-positive patients. While gastrointestinal symptoms
are observed infrequently (less than 5%) in adults infected with
seasonal inﬂuenza, more than one-ﬁfth of adult cases in our
series reported nausea and 25% reported diarrhea.
The clinical spectrum of novel H1N1 infection is still being
deﬁned, but both self-limited illness and severe outcomes,
including respiratory failure and death, have been observed.
In the United States surveillance, most conﬁrmed cases of
H1NI infection have been characterized by self-limited,
uncomplicated febrile respiratory illness and symptoms similar
to those of seasonal inﬂuenza (cough, sore throat, rhinorrhea,
headache, and myalgia), but approximately 38% of cases have
also involved vomiting or diarrhea, neither of which is typical
of seasonal inﬂuenza [8].
Compared with patients who had suspected 2009 pandemic
inﬂuenza A (H1N1) virus, patients with conﬁrmed 2009 pan-
demic inﬂuenza A (H1N1) virus had lower total leukocyte,
neutrophil, and lymphocyte counts and higher lactate dehy-
drogenase and creatine phosphokinase levels at presentation.
These patients may have had a higher viral load at presenta-
tion, which may have led to the apparent worsening of labora-
tory values. This observation may correlate with immune
system over-reaction to the viral infection, leading to the so-
called cytokine storm, which triggers inﬂammation and lung
damage that can lead to multiple organ failure and death [4].
Our data is consistent with China survey who reported
21.4% of patients had leukopenia, and 68.1% of adults and
92.3% of children had lymphopenia. None of the patients
had thrombocytopenia. The lymphopenia was transient. In
the same context, both leukocytosis and leukopenia were re-
ported in hospitalized patients in California [19,20].
Regarding illness severity in our cohort, some patients were
prone to severe complications, ARDS and respiratory failure
that necessitated an urgent transfer to the intensive care unit.
Cases presented with clinical features of acute respiratory ill-ness, all having radiographic conﬁrmation of pneumonia. A
striking percentage of hospitalized cases were severely ill, with
more than 3% requiring intensive care; most of them required
mechanical ventilation, this percent is much less than other re-
ports that reached up to 20%. The early start of oseltamivir in
all patients in our series may be the reasonable explanation.
Consistent with observational treatment studies suggested that
delayed initiation of oseltamivir treatment was associated with
severe 2009 H1N1 illness. The risk of severe disease increased
when oseltamivir treatment was started 2 days after illness on-
set, and initiation of treatment 4 days after onset was associ-
ated with a signiﬁcant risk of severe disease [16,21].
Moreover, bacterial co-infections in our cohort was less com-
mon than reported in other case series [16,22,23].
Of note, the seven patients with a severe clinical course in
our study had no comorbidities. The 2 deaths in our cohort,
were females, had viral pneumonia and acute respiratory dis-
tress syndrome. One of the two was 22 year old, pregnant in
her third trimester of pregnancy and had severe illness, ARDS,
transferred to ICU, required mechanical ventilation and died.
The other one had complication of multiorgan failure, shock,
DIC and Guillian Barre syndrome.
This is consistent with recent data suggesting increased hos-
pitalization rates and severity of illness associated with pan-
demic 2009 inﬂuenza A (H1N1), as well as observations of
inﬂuenza-associated excess deaths among pregnant women
during the previous pandemics of 1918–1919 and 1957–1958,
with risk increasing with advancing stages of pregnancy [22].
Pregnancy substantially increases the risk for severe respira-
tory illness and excess deaths during pandemics and seasonal
inﬂuenza. In UK surveillance, pregnant women comprised
18% of admissions among women aged 16–44 years compared
with an expected prevalence of 6% in the source population.
They reported that pregnant women are about three times
more likely to be admitted to hospital with H1N1 infection
than non-pregnant women of similar age and suggested the
importance of vaccinating pregnant women, which may also
protect their newborn infant [23].
Obesity has not previously been identiﬁed as an indepen-
dent risk factor for seasonal inﬂuenza complications [22]. An
association may have been obscured by a focus on the presence
of other comorbid risk factors associated with obesity, partic-
ularly in elderly persons. On the other hand, obesity has been
previously identiﬁed in many reports as an independent risk
factor for severe pandemic H1N1 infection [24,25]. Notably,
in China survey, obesity was identiﬁed as a risk factor for se-
vere illness among case patients 60 years of age, and multigrav-
ida pregnancy was a risk factor among pregnant case patients.
This observation possibly reﬂects the lack of reserve respira-
tory capacity in such individuals [16].
Obesity was expected to be more prominent cause in our
series because the cohort aged 17–43 years. Though H1N1 po-
sitive patients were signiﬁcantly more obese as compared to
those who are negative, small number of severe cases and
deaths in our cohort may obscure effect of obesity on
severity.
California public health surveillance data showed that fatal
cases in their series, is more likely to be obese. Further inves-
tigation is needed to clarify the association between obesity
and severe inﬂuenza and the pathophysiology underlying any
association. Even if obesity is only a proxy measure for other
underlying conditions, BMI data are an easily obtainable mea-
Risk factors and prognostic criteria in 230 patients with inﬂuenza A (H1N1) infection 7surement that maybe useful for quickly identifying patients to
target for treatment and prevention measures, similar to age
groupings. obesity may be a newly identiﬁed risk factor for
fatal pandemic 2009 inﬂuenza A(H1N1) infection and merits
further study [22].
The severe illness and deaths associated with seasonal inﬂu-
enza epidemics are in large part the result of secondary compli-
cations, including primary viral pneumonia, secondary
bacterial pneumonia (particularly with group A streptococcus,
Staphylococcus aureus, and Streptococcus pneumoniae) [26],
and exacerbations of underlying chronic conditions. The same
complications may occur with H1N1 infection. Patients who
are at highest risk for severe complications of H1N1infection
are likely to include but may not be limited to groups at high-
est risk for severe seasonal inﬂuenza: children under the age of
5 years, adults 65 years of age or older, children and adults of
any age with underlying chronic medical conditions, and preg-
nant women [8]. However, in contrast to recent studies that
suggest a severe clinical course in patients with at least one sig-
niﬁcant comorbidity [13,22,24], the patients with a severe clin-
ical course in our series had no more comorbidities than
patients with a non-severe clinical course.
Enhanced surveillance that was implemented in the United
States for human infection with inﬂuenza A viruses, showed
that 60% of patients were 18 years of age or younger suggests
that children and young adults may be more susceptible to
H1N1 infection than are older persons. It has been proposed
that elderly persons may have some level of cross-protection
against H1N1 infection from preexisting antibodies against
other inﬂuenza A (H1N1) viruses, as suggested by serologic
studies of the 1976 swine inﬂuenza vaccine and seasonal inﬂu-
enza viruses [4,22].
On comparison to UK surveillance, in our cohort, overall,
3% vs. 12% of UK patients required high dependency or
intensive care and 1.1% vs. 4.6% died; the mortality among
those requiring enhanced care was 28.6% vs. 31% of UK pa-
tients [23]. The median age of UK cases was 23 years and 46%
had risk factors for seasonal inﬂuenza complications.
Consistent with past pandemics, we found that patients
with a severe outcome were more likely to be young age, fe-
male sex, and have dyspnoea, leucopenia, neutropenia and
lymphopenia with high creatine phosphokinase level, and high
lactate dehydrogenase level. We also identiﬁed 2 independent
risk factors for illness severity in multivariate analysis, CPK
and lactate dehydrogenase levels greater than normal, that
probably reﬂects tissue damage.
In accordance, a previous study performed in H5N1-in-
fected mice showed that infection with the lethal strains of
the virus correlated with a profound drop in the lymphocyte
counts following their apoptosis, accompanied by diminished
synthesis of cytokines such as interleukin-1 and interferon-
gamma [27]. This suggests that certain pathogenic strains of
inﬂuenza virus might severely harm the immune system, result-
ing in disseminated and lethal disease. Therefore, we suggest
that CPK, LDH, leukopenia, neutropenia and lymphopenia
during hospitalization in severely ill H1N1 infected patients
might serve as a surrogate marker for the severity of the dis-
ease and its prognosis.
In UK surveillance and other reports showed that patients
with a severe outcome were more likely to be recorded as obese
and to have pulmonary disease other than asthma or COPD,
altered consciousness level, shortness of breath, pneumonia,CRP levelP 100 mg/l, peripheral oxygen saturation of
<94% on air or to have required supplemental oxygen or
intravenous ﬂuids on admission than those managed on stan-
dard wards. These ﬁndings are similar to those of previous
studies [23].
Our study has several limitations. One of the major limita-
tions of the current work is its retrospective nature that relied
on data collected from case records. Therefore, we may have
missed important information in some patients. Second, the
relatively small number of patients with a severe outcome.
Third, its restriction to hospitalized patients.
However, the design of the study is advantageous in its fo-
cus on a deﬁned group of admitted patients suspected of hav-
ing the infection, thus enabling reliable validation of
demographic, clinical and laboratory data on admission and
during the patients’ hospital course, as well as their clinical
outcomes. Obviously, it should be emphasized that the results
of the study are not applicable to the course of pandemic
(H1N1) 2009 virus infection in the non-admitted general pop-
ulation, but rather to patients whose clinical presentation was
severe enough to justify their admission.
In summary, our study shows that young age, female sex,
obesity and the presence of typical symptoms and signs of
inﬂuenza, including fever, cough, and sore throat in addition
to diarrhea are common indicator for pandemic (H1N1)
2009 virus positivity among clinically suspected patients. How-
ever, severe outcome was more conﬁned to young, female pa-
tients with dyspnoea, in addition to those with low (leukocyte,
neutrophil and/or lymphocyte) count, in addition to high cre-
atine phosphokinase and lactate dehydrogenase levels. These
results are in accordance with a previous report [11].
In conclusion, the data indicate that in contrast to the typ-
ical seasonal ﬂu that usually complicates patients in the ex-
treme age groups and who have signiﬁcant comorbidity, the
novel pandemic (H1N1) 2009 virus has an unexpected ten-
dency to complications in young and previously healthy peo-
ple. The more severe cases are characterized by increased
inﬂammatory markers, along with signiﬁcant leukopenia.
Most studies published to date have been limited by small sam-
ple size, retrospective design, analysis based merely on data-
base surveillance reports, or inclusion of only critically ill
patients [2]. Thus more prospective, and large sample size stud-
ies required to substantiate more knowledge on the natural his-
tory of the disease and risk factors for a more severe clinical
course among infected patients.References
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